Investor Presentation for the Quarter ended June 30, 2026 is attached herewith

Investor Presentation - Q1FY27 - Total Revenue 260.8 Cr +15% y-y; EBITDA 47.2 Cr (margin 18.09%, +350 bps y-y); PAT 22.0 Cr +82% y-y - Indore facility scale-up progressing with 30% capacity utilization; multiple global regulatory certifications underway - Hospital injectable platform expanding with new product launches and deeper hospital wallet share - Women's health platform maintains category leadership with pipeline of differentiated products - Botulinum toxin platform growing with new formulations and expanding therapeutic indications - International business shifting to IP-owned model with approvals in 8 countries and EU marketing authorization - Robust R&D focus on peptides, novel drug delivery systems, and clinical programs - Strategic initiatives include market share growth in botulinum toxins, immuno-oncology commercialization, and contract manufacturing expansion